Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000922 · ClinicalTrials.gov registry record · NA

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

A NA study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
NA
Development phase
1,710
Enrollment target
17
Study locations

NCT00000922 is a NA study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 1,710 participants, above the 443-participant average among 542 other HIV Infections trials with a reported enrollment target (286% higher). The trial reports 17 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000922, a NA study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
NA
Development phase
1,710 participants
Enrollment target
17
Study locations

Study Summary

The purpose of this study is to determine whether it is better to start an anti-HIV regimen containing a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a PI in combination with an NNRTI. This study will also examine which treatment regimen is best as a first treatment for HIV infection.

Conditions Studied

HIV Infections

Interventions

  • DRUG Efavirenz
  • DRUG Indinavir sulfate
  • DRUG Nelfinavir mesylate
  • DRUG Nevirapine
  • DRUG Abacavir sulfate

Study Locations (17)

Michigan

  • Wayne State Univ - WSU/DMC / Univ Hlth Ctr - Detroit
  • Henry Ford Hosp - Detroit

New Jersey

  • Southern New Jersey AIDS Cln Trials / Dept of Med - Camden
  • North Jersey Community Research Initiative - Newark

California

  • Community Consortium / UCSF - San Francisco

Colorado

  • Denver CPCRA / Denver Public Hlth - Denver

Connecticut

  • Yale Univ School of Medicine / AIDS Program - New Haven

District of Columbia

  • Washington Reg AIDS Prog / Dept of Infect Dis - Washington D.C.

Georgia

  • AIDS Research Consortium of Atlanta - Atlanta

Illinois

  • AIDS Research Alliance - Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 1,710 participants
Est. Completion 2006-06
Phase NA

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000922

The ClinicalTrials.gov registry entry for NCT00000922 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,710 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 443-participant average among 542 other HIV Infections trials with a reported enrollment target (286% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 5 interventions - of which Efavirenz is the first listed.

NCT00000922 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Michigan, New Jersey, California.

Frequently Asked Questions

What is clinical trial NCT00000922 about?

NCT00000922 is a clinical study titled "A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)". The purpose of this study is to determine whether it is better to start an anti-HIV regimen containing a protease inhibitor (PI), a non-nucleoside reverse transcriptase inhibitor (NNRTI), or a PI in combination with an NNRTI. This study will also examine which treatment regimen is best as a first tr...

What is the current status of trial NCT00000922?

This trial is currently completed. It is a NA study. The enrollment target is 1,710 participants. Estimated completion is 2006-06.

What conditions does trial NCT00000922 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000922?

The interventions under investigation include: Efavirenz (DRUG), Indinavir sulfate (DRUG), Nelfinavir mesylate (DRUG), Nevirapine (DRUG), Abacavir sulfate (DRUG).

Who is sponsoring clinical trial NCT00000922?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000922 being conducted?

This trial has 17 study locations across California, Colorado, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.